Otsuka Pharmaceutical Co., Ltd. – FDA 483, Oct 22, 2019
Otsuka Pharmaceutical Co., Ltd. in Naka-Gun, Tokushima, Japan, was inspected and cited for significant deficiencies across its quality system, particularly concerning foreign particle contamination in drug products. The inspection revealed a systemic failure to thoroughly investigate discrepancies, identify root causes for contamination and customer complaints, and maintain adequate control over equipment, documentation, and computer systems. These issues indicate a severe lack of quality oversight impacting the safety, purity, and efficacy of drug products.
ID · d3b34d94-f15f-409d-b27b-8a21017a34f0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.